Cytta CORP

Market Movers (8-K)

OTC.Pink
Cytta Corp. filed an amendment to its 8-K disclosing a disagreement with its former auditor, Sadler, Gibb & Associates, regarding accounting treatments for convertible notes and warrants.
Worse than expected
Delay expected
OTC.Pink
Cytta Corp. announced the dismissal of Sadler, Gibb and Associates, LLC and the appointment of RBSM LLP as its new independent registered public accounting firm.
OTC.Pink
Cytta Corp. announced it will restate its December 31, 2024 interim financial statements due to a $36,976 revenue recognition error from unverified sales orders.
Worse than expected
Delay expected
OTC.Pink
Cytta Corp. has entered a new agreement with Genesys Technologies to integrate advanced Wi-VHFi mobile broadband technology into its Cytta Labs incubator, while also disclosing a restatement of its December 2024 financial statements due to a revenue recognition error.
Capital raise
Worse than expected
OTC.Pink
Cytta Corp.'s former auditor, Prager Metis CPAs, LLC, has publicly disagreed with the company's statements in a recent 8-K filing, citing materially misstated financial statements due to fraudulent sales orders and a lack of access to critical review materials.
Worse than expected
OTC.Pink
Cytta Corp. has dismissed its independent registered public accounting firm, Prager Metis CPAs, LLC, citing the cost of an additional forensic audit required to investigate fraudulent sales orders, despite the company's own review confirming the fraud.
Worse than expected

Quarterly Earnings (10-Q)

OTC.Pink
Cytta Corp. reported a significant net income for the nine months ended June 30, 2025, primarily driven by an unrealized gain on marketable securities, despite continued operational losses and a going concern warning.
Delay expected
Capital raise
OTC.Pink
Cytta Corp. reported a significant shift to net income for the six months ended March 31, 2025, primarily driven by a substantial unrealized gain on marketable securities, despite continued limited operational revenue.
Delay expected
Worse than expected
Capital raise
OTC.Pink
Cytta Corp. filed an amended quarterly report, restating its Q4 2024 financials due to misstatements from fraudulent sales orders, revealing a deeper net loss and significant internal control weaknesses.
Capital raise
Worse than expected
OTC.Pink
Cytta Corp's Q1 2025 shows revenue growth driven by subscription agreements, but the company still faces significant financial challenges and doubts about its ability to continue as a going concern.
Delay expected
Worse than expected
Capital raise
OTC.Pink
Cytta Corp. reported a decrease in revenue and an increase in operating expenses for the third quarter of 2024, alongside a net loss of $1.45 million.
Worse than expected
Capital raise
OTC.Pink
Cytta Corp.'s Q2 2024 results show a decrease in revenue and an increase in operating expenses, leading to a net loss of $2,047,669 for the six-month period ending March 31, 2024.
Worse than expected
Capital raise

Annual Reports (10-K)

OTC.Pink
Cytta Corp.'s 10-K filing reveals a net loss for fiscal year 2024 and raises substantial doubt about the company's ability to continue as a going concern.
Delay expected
Capital raise
Worse than expected
OTC.Pink
Cytta Corp.'s annual 10-K filing reveals a year of increased revenue but also significant operating losses and concerns about the company's ability to continue as a going concern.
Capital raise
Worse than expected